ME/CFS and Orthostatic Intolerance: Why Standing Up Makes Everything Worse

Orthostatic intolerance (OI) — the worsening of symptoms when standing or sitting upright — is one of the most prevalent and underrecognized features of ME/CFS. Studies suggest that 70–90% of ME/CFS patients have some form of OI, yet it is frequently missed in clinical evaluations because patients are often assessed while lying down or seated, and because the connection between upright posture and symptom worsening is not always obvious.

Understanding and treating OI can produce dramatic improvements in ME/CFS symptoms, even when the underlying ME/CFS itself remains challenging to treat.

Why Orthostatic Intolerance Occurs in ME/CFS

When a healthy person stands up, the autonomic nervous system rapidly compensates for the gravitational pooling of blood in the lower body by increasing heart rate, constricting blood vessels, and maintaining blood pressure. In ME/CFS, this compensatory response is impaired.

The exact mechanism is not fully understood, but several factors appear to contribute:

• Reduced blood volume: Many ME/CFS patients have significantly reduced circulating blood volume (hypovolemia), leaving less blood available to maintain perfusion when upright.
• Autonomic nervous system dysfunction: Impaired sympathetic vasoconstriction allows blood to pool in the legs and abdomen when upright, reducing cerebral perfusion.
• Small fiber neuropathy: Damage to the small autonomic nerve fibers that control blood vessel tone is present in a significant proportion of ME/CFS patients and directly impairs the orthostatic response.
• Neuroinflammation: Inflammatory processes in the brainstem and hypothalamus may disrupt the central autonomic control centers.

Forms of Orthostatic Intolerance in ME/CFS

POTS (Postural Orthostatic Tachycardia Syndrome)

POTS is the most common form of OI in ME/CFS, present in approximately 30–40% of patients. It is defined by a heart rate increase of ≥30 bpm (≥40 bpm in adolescents) within 10 minutes of standing, in the absence of orthostatic hypotension.

POTS in ME/CFS often presents as the "neuropathic" subtype, associated with reduced blood volume and impaired peripheral vasoconstriction, rather than the hyperadrenergic subtype more common in primary POTS.

Neurally Mediated Hypotension (NMH)

NMH — also called vasovagal syncope or neurocardiogenic syncope — involves a paradoxical drop in blood pressure and heart rate after a period of upright posture. It is distinct from POTS (which involves tachycardia) and can cause fainting or near-fainting. NMH is common in ME/CFS and was one of the first autonomic abnormalities documented in the condition.

Cerebral Blood Flow Reduction Without Classic POTS

Some ME/CFS patients have significant reductions in cerebral blood flow when upright that do not meet the heart rate criteria for POTS. This "cerebral hypoperfusion" can cause severe cognitive symptoms, brain fog, and fatigue when upright, even without tachycardia. It can be detected with transcranial Doppler ultrasound or specialized tilt table testing.

Recognizing OI in ME/CFS

OI in ME/CFS is often missed because patients adapt to it unconsciously — lying down frequently, avoiding standing activities, and not connecting their symptom worsening to posture. Key signs to look for:

• Symptoms that are significantly worse when standing or sitting upright compared to lying down
• Improvement in cognitive symptoms, fatigue, or pain when horizontal
• Worsening after prolonged standing (shopping, cooking, waiting in line)
• Preference for lying down even when not tired
• Feeling better in the morning (after a night horizontal) than in the afternoon
• Palpitations, dizziness, or lightheadedness when standing

The NASA Lean Test

The NASA Lean Test is a simple at-home assessment for orthostatic intolerance that can be performed without a tilt table. It involves measuring heart rate and blood pressure while lying down and after 10 minutes of standing with the back against a wall (to minimize muscle pumping).

A heart rate increase of ≥30 bpm during the test is consistent with POTS. Symptoms that worsen during the test (brain fog, fatigue, nausea, palpitations) are also significant, even without meeting the strict heart rate criteria.

Treatment

Treatment of OI in ME/CFS follows the same principles as treatment of primary POTS:

Non-pharmacological (first line):

• Increased fluid intake (2–3 liters daily)
• Increased sodium intake (3–5g daily, or as tolerated)
• Compression garments (waist-high, 20–30 mmHg)
• Elevation of the head of the bed (10–30 degrees)
• Recumbent or semi-recumbent exercise (rowing, swimming, recumbent cycling)
• Avoiding prolonged standing and heat exposure

Pharmacological:

• Beta-blockers (propranolol, metoprolol) for heart rate control
• Ivabradine for heart rate reduction without blood pressure effects
• Fludrocortisone for blood volume expansion
• Midodrine for blood pressure support
• Pyridostigmine (Mestinon) — particularly useful in ME/CFS-associated OI

Important caveat for ME/CFS: Exercise programs for OI must be approached with extreme caution in ME/CFS patients with PEM. Upright exercise that exceeds the anaerobic threshold can trigger crashes. Recumbent exercise (lying flat or semi-reclined) is the safest starting point.

The Impact of Treating OI on ME/CFS Symptoms

For ME/CFS patients with significant OI, treating the orthostatic component often produces improvements in cognitive function, fatigue, and overall function that are disproportionately large relative to the specific OI treatment. This suggests that cerebral hypoperfusion when upright may be a major driver of ME/CFS symptoms in many patients — and that addressing it directly is one of the highest-yield interventions available.